Objective: To probe into the clinical value of letrozole in the adjuvant treatment of boys with growth hormone-deficient short stature. Methods: Retrospective analysis was performed on the clinical data of 80 boys with growth hormone-deficient short stature admitted into the Second Affiliated Hospital of Anhui Medical University from Mar. 2016 to Jun. 2018. All patients were divided into the study group and the control group according to different treatment regimens

with 40 cases in each group. The control group was given growth hormone therapy

while the study group received letrozole combined with growth hormone therapy for 2 years. The physical development indicators (height

body weight

predicted height

growth rate)

bone age

bone mineral density distal radius bone mass (SOS)

glucose and lipid metabolism indicators such as triacylglycerol (TG)

total cholesterol (TC)

fasting blood glucose (FBG)

fasting insulin (FINS)

serum insulin growth factor such as insulin-like growth factor binding protein-3 (IGFBP-3) and insulin-like growth factor-1 (IGF-1)

nesfatin-1

and ghrelin levels before treatment and after treatment of 1 year and 2 years were compared between two groups. The incidence of adverse drug reactions between two groups was recorded. Results: The levels of TC in two groups after treatment of 1 year and 2 years were lower than those before treatment

and the levels of FBG and FINS were higher than those before treatment (P<0.05). The height

body weight

growth rate

SOS

IGFBP-3 and IGF-1 levels in the study group were higher than those in the control group after treatment of 1 year and 2 years

while the nesfatin-1 and ghrelin levels were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions (22.50% in the study group and 17.50% in the control group) between two groups (P>0.05) Conclusion: Letrozole combined with growth hormone can further inhibit the expression of serum nesfatin-1 and ghrelin

up-regulate the serum levels of IGFBP-3 and IGF-1

and promote the physical development of boys with growth hormone-deficient short stature

with lower incidence of adverse drug reactions and higher clinical application value.